These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 32047597)

  • 1. Mycobacterial virulence: impact on immunogenicity and vaccine research.
    Kroesen VM; Madacki J; Frigui W; Sayes F; Brosch R
    F1000Res; 2019; 8():. PubMed ID: 32047597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Impact of Genome Region of Difference 4 (RD4) on Mycobacterial Virulence and BCG Efficacy.
    Ru H; Liu X; Lin C; Yang J; Chen F; Sun R; Zhang L; Liu J
    Front Cell Infect Microbiol; 2017; 7():239. PubMed ID: 28642843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of mutant mycobacteria as new vaccines to prevent tuberculosis.
    Hernàndez Pando R; Aguilar LD; Infante E; Cataldi A; Bigi F; Martin C; Gicquel B
    Tuberculosis (Edinb); 2006; 86(3-4):203-10. PubMed ID: 16542875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BCG vaccines: their mechanisms of attenuation and impact on safety and protective efficacy.
    Liu J; Tran V; Leung AS; Alexander DC; Zhu B
    Hum Vaccin; 2009 Feb; 5(2):70-8. PubMed ID: 19164935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new tool for tuberculosis vaccine screening: Ex vivo Mycobacterial Growth Inhibition Assay indicates BCG-mediated protection in a murine model of tuberculosis.
    Zelmer A; Tanner R; Stylianou E; Damelang T; Morris S; Izzo A; Williams A; Sharpe S; Pepponi I; Walker B; Hokey DA; McShane H; Brennan M; Fletcher H
    BMC Infect Dis; 2016 Aug; 16():412. PubMed ID: 27519524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protection by novel vaccine candidates, Mycobacterium tuberculosis ΔmosR and ΔechA7, against challenge with a Mycobacterium tuberculosis Beijing strain.
    Marcus SA; Steinberg H; Talaat AM
    Vaccine; 2015 Oct; 33(42):5633-5639. PubMed ID: 26363381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BCG-mediated protection against M. tuberculosis is sustained post-malaria infection independent of parasite virulence.
    Tangie E; Walters A; Hsu NJ; Fisher M; Magez S; Jacobs M; Keeton R
    Immunology; 2022 Feb; 165(2):219-233. PubMed ID: 34775598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mycobacterium tuberculosis virulence: insights and impact on vaccine development.
    Delogu G; Provvedi R; Sali M; Manganelli R
    Future Microbiol; 2015; 10(7):1177-94. PubMed ID: 26119086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Promising Listeria-Vectored Vaccine Induces Th1-Type Immune Responses and Confers Protection Against Tuberculosis.
    Yin Y; Lian K; Zhao D; Tao C; Chen X; Tan W; Wang X; Xu Z; Hu M; Rao Y; Zhou X; Pan Z; Zhang X; Jiao X
    Front Cell Infect Microbiol; 2017; 7():407. PubMed ID: 29034213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developing whole mycobacteria cell vaccines for tuberculosis: Workshop proceedings, Max Planck Institute for Infection Biology, Berlin, Germany, July 9, 2014.
    Whole Mycobacteria Cell Vaccines for Tuberculosis Summary Group
    Vaccine; 2015 Jun; 33(26):3047-55. PubMed ID: 25882170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ESX-5-targeted export of ESAT-6 in BCG combines enhanced immunogenicity & efficacy against murine tuberculosis with low virulence and reduced persistence.
    Heijmenberg I; Husain A; Sathkumara HD; Muruganandah V; Seifert J; Miranda-Hernandez S; Kashyap RS; Field MA; Krishnamoorthy G; Kupz A
    Vaccine; 2021 Dec; 39(50):7265-7276. PubMed ID: 34420788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New tuberculosis vaccines based on attenuated strains of the Mycobacterium tuberculosis complex.
    Collins DM
    Immunol Cell Biol; 2000 Aug; 78(4):342-8. PubMed ID: 10947858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Attenuated Mycobacterium tuberculosis SO2 vaccine candidate is unable to induce cell death.
    Aporta A; Arbues A; Aguilo JI; Monzon M; Badiola JJ; de Martino A; Ferrer N; Marinova D; Anel A; Martin C; Pardo J
    PLoS One; 2012; 7(9):e45213. PubMed ID: 23028853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential productions of lipid virulence factors among BCG vaccine strains and implications on BCG safety.
    Chen JM; Islam ST; Ren H; Liu J
    Vaccine; 2007 Nov; 25(48):8114-22. PubMed ID: 17954004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of live attenuated persistent and rapidly cleared Mycobacterium tuberculosis vaccine candidates in non-human primates.
    Larsen MH; Biermann K; Chen B; Hsu T; Sambandamurthy VK; Lackner AA; Aye PP; Didier P; Huang D; Shao L; Wei H; Letvin NL; Frothingham R; Haynes BF; Chen ZW; Jacobs WR
    Vaccine; 2009 Jul; 27(34):4709-17. PubMed ID: 19500524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consequence of enhanced LC3-trafficking for a live, attenuated M. tuberculosis vaccine.
    Köster S; Klevorn T; Papavinasasundaram K; Sassetti CM; Portal-Celhay C; Philips JA
    Vaccine; 2018 Feb; 36(7):939-944. PubMed ID: 29343411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of proteomics on anti-Mycobacterium tuberculosis (MTB) vaccine development.
    Jagusztyn-Krynicka EK; Roszczenko P; Grabowska A
    Pol J Microbiol; 2009; 58(4):281-7. PubMed ID: 20380137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of Lipid Virulence Factors Reduces the Efficacy of the BCG Vaccine.
    Tran V; Ahn SK; Ng M; Li M; Liu J
    Sci Rep; 2016 Jun; 6():29076. PubMed ID: 27357109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Live tuberculosis vaccines based on phoP mutants: a step towards clinical trials.
    Asensio JA; Arbués A; Pérez E; Gicquel B; Martin C
    Expert Opin Biol Ther; 2008 Feb; 8(2):201-11. PubMed ID: 18194076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyper-attenuated MTBVAC erp mutant protects against tuberculosis in mice.
    Solans L; Uranga S; Aguilo N; Arnal C; Gomez AB; Monzon M; Badiola JJ; Gicquel B; Martin C
    Vaccine; 2014 Sep; 32(40):5192-7. PubMed ID: 25066740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.